Dysport™ was approved by the Food and Drug Administration on 29 April 2009 for two separate indications, the treatment of cervical dystonia to reduce the severity of abnormal head position and neck pain in both toxin-naive and previously treated patients, and the temporary improvement in the appearance of moderate to severe glabellar lines in adults younger than 65 years of age. Ipsen will market DYSPORT™ in the United States for the therapeutic indication (cervical dystonia), while Medicis already markets DYSPORT™ in the U.S. for the aesthetic indication (glabellar lines).